{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:31:49Z","timestamp":1792031509451,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.eururo.2017.06.027","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T05:45:49Z","timestamp":1500097549000},"page":"156-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer"],"prefix":"10.1016","volume":"73","author":[{"given":"Daniel E.","family":"Spratt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert T.","family":"Dess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Zumsteg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel W.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuoc T.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel S.","family":"Antonarakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Posadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix Y.","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.06.027_bib0245","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jama.2015.6036","article-title":"Trends in management for patients with localized prostate cancer, 1990\u20132013","volume":"314","author":"Cooperberg","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2017.06.027_bib0250","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0255","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.06.027_bib0260","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent\u2014update 2013","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2014.11.018","article-title":"Natural history of surgically treated high-risk prostate cancer","volume":"33","author":"Briganti","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0270","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.eururo.2015.04.003","article-title":"Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National Cancer Data Base","volume":"68","author":"Sineshaw","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0275","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0280","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jama.299.3.289","article-title":"Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial","volume":"299","author":"D\u2019Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2017.06.027_bib0285","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.027_bib0290","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0295","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0300","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2014long-term results of phase III RTOG 85\u201331","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2017.06.027_bib0305","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(11)70063-8","article-title":"Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial","volume":"12","author":"Denham","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0310","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.027_bib0315","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0320","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0325","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0330","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.027_bib0335","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.juro.2013.05.032","article-title":"Adjuvant and salvage radiotherapy after prostatectomy: AUA\/ASTRO guideline","volume":"190","author":"Thompson","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0340","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ijrobp.2013.05.029","article-title":"Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology\/American Urological Association guidelines","volume":"86","author":"Valicenti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2017.06.027_bib0345","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2011.29.7_suppl.1","volume":"29","author":"Shipley","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0355","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2007.08.041","article-title":"Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials","volume":"53","author":"Collette","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0360","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","article-title":"Prognostic Gleason grade grouping: data based on the modified Gleason scoring system","volume":"111","author":"Pierorazio","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.06.027_bib0365","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0370","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/bju.13488","article-title":"Independent surgical validation of the new prostate cancer grade-grouping system","volume":"118","author":"Spratt","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.06.027_bib0375","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/pcan.2016.18","article-title":"Independent validation of the prognostic capacity of the ISUP prostate cancer grade grouping system for radiation treated patients with long-term follow-up","volume":"19","author":"Spratt","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2017.06.027_bib0380","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.027_bib0385","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0390","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0395","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2017.06.027_bib0400","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","article-title":"Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis","volume":"68","author":"Bosco","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0405","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1158\/1078-0432.CCR-13-3366","article-title":"Overdetection of recurrence after radical prostatectomy: estimates based on patient and tumor characteristics","volume":"20","author":"Xia","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.06.027_bib0410","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1002\/cncr.23084","article-title":"Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?","volume":"110","author":"Bylow","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2017.06.027_bib0415","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijrobp.2016.06.2445","article-title":"Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01\/05 randomized phase 3 trial","volume":"96","author":"Zapatero","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2017.06.027_bib0420","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.06.027_bib0425","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.eururo.2016.03.010","article-title":"The effect of salvage radiotherapy and its timing on the health-related quality of life of prostate cancer patients","volume":"70","author":"van Stam","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0430","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.eururo.2016.11.015","article-title":"Functional outcomes and quality of life after radical prostatectomy only versus a combination of prostatectomy with radiation and hormonal therapy","volume":"71","author":"Adam","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0435","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ijrobp.2016.08.043","article-title":"Salvage radiation therapy dose response for biochemical failure of prostate cancer after prostatectomy\u2014a multi-institutional observational study","volume":"96","author":"Pisansky","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2017.06.027_bib0440","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1200\/JCO.2015.63.3529","article-title":"Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09\/10","volume":"33","author":"Ghadjar","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0445","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijrobp.2007.02.035","article-title":"Radiotherapy after prostatectomy: improved biochemical relapse-free survival with whole pelvic compared with prostate bed only for high-risk patients","volume":"69","author":"Spiotto","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2017.06.027_bib0450","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00066-015-0872-9","article-title":"Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: a propensity score-matched analysis","volume":"191","author":"Song","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0455","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/cncr.27712","article-title":"Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy","volume":"119","author":"Moghanaki","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2017.06.027_bib0460","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13026","article-title":"Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review","volume":"116","author":"Kunath","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2017.06.027_bib0465","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eururo.2015.05.009","article-title":"Duration of androgen deprivation therapy influences outcomes for patients receiving radiation therapy following radical prostatectomy","volume":"69","author":"Jackson","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0470","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0475","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1200\/JCO.2016.70.2811","article-title":"Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease","volume":"35","author":"Spratt","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.06.027_bib0480","doi-asserted-by":"crossref","unstructured":"Zhao SG, Chang SL, Erho N, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. In press. http:\/\/dx.doi.org\/10.1001\/jamaoncol.2017.0751.","DOI":"10.1001\/jamaoncol.2017.0751"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817305274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817305274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T02:23:20Z","timestamp":1535595800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817305274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0302283817305274"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.06.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}